Regulatory approval for Asahi Kasei-Calliditas deal by mid-2024? | Binary | | | 7 months ago | |
Asahi Kasei's pharmaceutical revenue up significantly by end of 2025? | Binary | | | 7 months ago | |
Impact on Asahi Kasei's stock price post-Calliditas acquisition announcement | Categorical | | | 7 months ago | |
Number of pharmaceutical acquisitions by Asahi Kasei by end of 2025 | Categorical | | | 7 months ago | |
Asahi Kasei completes acquisition of Calliditas by end of 2024? | Binary | | | 7 months ago | |
Market position of Asahi Kasei's pharma sector by end of 2025 | Categorical | | | 7 months ago | |
Will Travere Therapeutics' stock price increase by 20% or more by the end of 2024? | Binary | | | 4 months ago | |
Will FILSPARI achieve $500 million in sales by the end of 2024? | Binary | | | 4 months ago | |
Will Novartis announce a new IgA nephropathy treatment by the end of 2024? | Binary | | | 4 months ago | |
Which company will have the highest market share in IgA nephropathy treatments by the end of 2024? | Categorical | | | 4 months ago | |
What will be Travere Therapeutics' stock price at the end of 2024? | Categorical | | | 4 months ago | |
Who will be the first major competitor to launch a non-immunosuppressive IgA nephropathy treatment after FILSPARI's approval? | Categorical | | | 4 months ago | |
